ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Endoplasmic reticulum stress-based ATF6 signaling pathway: evaluation of 4-PBA improving retinal state in myopic guinea pigs.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study aims to evaluate whether 4-phenylbutyric acid (4-PBA) ameliorates retinal damage in myopic Cavia porcellus by inhibiting endoplasmic reticulum stress (ERS)-mediated activating transcription factor 6 (ATF6) signaling pathway activation and suppressing downstream apoptotic cascades. Lens-induced myopia (LIM) was established in Cavia porcellus with a - 6.0 D lens placed on the right eye. Animals were divided into six groups: normal control (NC), LIM, LIM + SHAM (vehicle), and LIM + 4-PBA (low/medium/high doses: 60/120/240 mg/kg). Interventions lasted 4-6 weeks. Ocular parameters (refractive error, axial length) and retinal thickness (SD-OCT) were measured. Retinal function was assessed via flash electroretinography (FERG). Molecular mechanisms were analyzed through qPCR/Western blot for ATF6/glucose-regulated protein 78 (GRP78)/C/EBP homologous protein (CHOP)/Bcl-2-associated X protein (Bax)/B cell lymphoma 2 (Bcl-2) expression; immunofluorescence and co-immunoprecipitation (Co-IP) of ATF6-GRP78 interactions; flow cytometry for apoptosis (Annexin V/PI), ROS, and mitochondrial membrane potential (JC-1); calcium flux dynamics (non-invasive micro-test technology); and molecular docking of 4-PBA with ATF6/GRP78. LIM groups exhibited significant axial elongation and myopic refraction vs. NC (P < 0.05). 4-PBA remarkably attenuated axial elongation, accompanied by a dose-dependent manner (P < 0.001). Retinas in the LIM group showed thinning, disorganized layers, and reduced FERG amplitudes (Cone-b/Rod-b/OPs). By contrast, 4-PBA restored thickness and electrophysiological responses. ATF6, GRP78, and CHOP expression as well as calcium flux increased in LIM retinas, whereas 4-PBA suppressed these trends at a dose-dependent manner. Additionally, elevated ROS, mitochondrial dysfunction, Bax upregulation, Bcl-2 downregulation, and increased apoptosis occurred in the LIM Cavia porcellus. Nevertheless, 4-PBA treatment could effectively improve these effects. 4-PBA mitigates retinal damage in myopia by inhibiting ATF6-mediated ERS, reducing calcium overload, restoring mitochondrial function, and suppressing the ATF6-CHOP-Bax apoptotic cascade. This study identifies the ATF6 pathway as a therapeutic target for myopic retinopathy and supports 4-PBA's potential as a retinal protective agent.
Indexed as
Identifiers
41910728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.